Abstract
Hereditary mixed polyposis syndrome (HMPS), characterized by hyperplastic, juvenile, admixed, serrated adenomas and eventually colorectal cancer, is managed by repeated polypectomy and surgery. We determined if HMPS polyps express cyclooxygenase-2 (COX-2). Nineteen recent HMPS polyps, from five family members, were stained for COX-2. Polyps’ epithelium and stroma and comparison tissues (normal colonic mucosa [9], sporadic juvenile polyps [18], colorectal cancers [3]) were quantified for COX-2 by: area of staining (0–3) × intensity (0–3). Epithelial, stromal, and total scores were evaluated in relationship to histology and dysplasia. HMPS polyps COX-2 mean epithelial (5.0 ± 3.0), stromal (6.9 ± 1.9), and total (11.8 ± 4.6) scores were significantly higher (P&<0.01) than sporadic juvenile polyps (0.6 ± 0.7, 3.1 ± 2.2, and 3.6 ± 2.2 respectively), while colorectal cancer scored 9, 9, and 18. There was a positive association (P&<0.01) among histology, degree of dysplasia, and COX-2 expression. COX-2 expression in HMPS polyps and its association with dysplasia suggest that chemoprevention might be a useful adjunct therapy.
Similar content being viewed by others
References
Jaeger EEM, Woodford-Richens KL, Lockett M, Rowan AJ, Sawyer EJ, Heinimann K, Rozen P, Murday VA, Whitelaw SC, Ginsberg A, Atkin WS, Lynch HT, Southey MC, Debinski H, Eng C, Bodmer WF, Talbot IC, Hodgson SV, Thomas HJW, Tomlinson IPM: An ancestral Ashkenazi haplotype at the HMPS/CRAC1 locus on 15q13-q14 is associated with Hereditary Mixed Polyposis Syndrome. Am J Hum Genet 72:1261–1267, 2003
Rozen P, Samuel Z, Brazowski E: A prospective study of the clinical, genetic, screening and pathological features of a family with hereditary mixed polyposis syndrome. Am J Gastroenterol 98:2317–2320, 2003
Steinbach G, Lynch PM, Philips RKS, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946–1952, 2000
Rossi DJ, Ylikorkala A, Korsisaari N, Salovaara R, Luukko K, Launonen V, Henkemeyer, Ristimäki A, Aaltonen LA, Mäkelä TP: Induction of cyclooxygenase-2 in a mouse model of Peutz-Jegher polyposis. Proc Natl Acad Sci USA 99:12327–12332, 2002
McGarrity TJ, Peiffer LP, Amos CI, Frazier ML, Ward MG, Howett MK: Overexpression of cyclooxygenase 2 in hamartomatous polyps of Peutz-Jeghers Syndrome. Am J Gastroenterol 98:671–678, 2003
Rozen P, Samuel Z, Brazowski E, Jakubowicz M, Rattan J, Halpern Z: An audit of familial juvenile polyposis at the Tel Aviv Medical Center: demographic, genetic and clinical features. Fam Cancer 2:1–7, 2003
Sonoshita M, Takaku K, Oshima M, Sugihara K, Taketo MM: Cyclooxygenase-2 expression in fibroblasts and endothelial cells of intestinal polyps. Cancer Res 62:6846–6849, 2002
Takeda H, Sonoshita M, Oshima H, Sugihara K-I, Chulada PC, Langenbach R, Oshima M, Taketo MM: Cooperation of cyclooxygenase 1 and cyclooxygenase 2 in intestinal polyposis. Cancer Res 63:4872–4877, 2003
Kune GA, Kune S, Watson LF: Colorectal cancer risk, chronic illnesses, operations, and medications: Case control results from the Melbourne Colorectal Cancer Study. Cancer Res 48:4399–4404, 1988
Thun MJ, Namboodiri MM, Heath CW Jr: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325:1593–1596, 1991
Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztess R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R: A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348:883–890, 2003
Benamouzig R, Deyra J, Martin A, Girard B, Julian E, Piednoir B, Couturier D, Coste T, Little J, Chaussade S, for The Association Pour La Prevention Par L’ Aspirine due Cancer Colorectal Study Group: Daily soluble aspirin and prevention of colorectal adenoma recurrence: One-year results of the APACC trial. Gastroenterology 125:328–336, 2003
Sørensen HT, Friis S, Nørgård B, Mellemkjær L, Blot WJ, McLaughlin JK, Ekbom A, Baron JA: Risk of cancer in a large cohort of nonaspirin NSAID users: A population-based study. Br J Cancer 88:1687–1692, 2003
Arao J, Sano Y, Fujii T, Shigeharu K, Fu KI, Yoshino T, Ochiai A, Fujimori T, Yoshida S: Cyclooxygenase-2 is overexpressed in serrated adenoma of the colorectum. Dis Colon Rectum 44:1319–1323, 2001
Takeuchi M, Kobayashi M, Ajioka Y, Honma T, Suzuki Y, Azumaya M, Narisawa R, Hayashi S-I, Asakura H: Comparison of cyclo-oxygenase 2 expression in colorectal serrated adenomas to expression in tubular adenomas and hyperplastic polyps. Int J Colorectal Dis 17:144–149, 2002
Kawada M, Seno H, Wada M, Suzuki K, Kanda N, Kayahara T, Fukui H, Sawada M, Kajiyama T, Sakai M, Chiba T: Cyclooxygenase-2 expression and angiogenesis in gastric hyperplastic polyp—Association with polyp size. Digestion 67:20–24, 2003
Chapple KS, Cartwright EJ, Hawcroft G, Tisbury A, Bonifer C, Scott N, Windsor ACJ, Guillou PJ, Markham AF, Coletta PL, Hull MA: Localization of cyclooxygenase-2 in human sporadic colorectal adenomas. Am J Pathol 156:545–553, 2000
Sato T, Yoshinaga K, Okabe S, Enomoto M, Takizawa T, Sugihara K: Cyclooxygenase-2 expression in colorectal adenomas. Dis Colon Rectum 46:786–792, 2003
Einspahr JG, Krouse RS, Yochim JM, Danenberg PV, Danenberg KD, Bhattacharyya AK, Martínez ME, Alberts DS: Association between cyclooxygenase expression and colorectal adenoma characteristics. Cancer Res 63:3891–3893, 2003
Bamba H, Ota S, Kato A, Adachi, A, Itoyama S, Matsuzaki F: High expression of cyclooxygenase-2 in macrophages of human colonic adenoma. Int J Cancer 83:470–475, 1999
Yamauchi T, Watanabe M, Kubota T, Hasegawa H, Yoshiyuki I, Endo T, Kabeshima Y, Yorozuya K, Yamamoto K, Mukai M, Kitajima M: Cyclooxygenase-2 expression as a new marker for patients with colorectal cancer. Dis Colon Rectum 45:98–103, 2002
Garewal H, Ramsey L, Fass R, Hart NK, Payne CM, Berstein H, Bernstein C: Perils of immunohistochemistry. Dig Dis Sci 48:197–202, 2003
Ohno S, Suzuki N, Ohno Y, Inagawa H, Soma G-I, Inoue M: Tumor-associated macrophages: Foe or accomplice of tumors? Anticancer Res 23:4395–4410, 2003
Balkwill F, Mantovani A: Inflammation and cancer: Back to Virchow ? Lancet 357:539–545, 2001
Sica A, Saccani A, Mantovani A: Tumor-associated macrophages: A molecular perspective. Int Immunopharmacol 2:1045–1054, 2002
Ladabaum U, Scheiman JM, Fendrick AM: Potential effect of cyclooxygenase-2-specific inhibitors on the prevention of colorectal cancer: a cost-effectiveness analysis. Am J Med 114:546–554, 2003
Cruz-Correa M, Hylind LM, Romans KE, Booker SV, Giardiello FM: Long-term treatment with sulindac in familial adenomatous polyposis: A prospective cohort study. Gastroenterology 122:641–645, 2002
Rüschoff J, Wallinger S, Dietmaier W, Bocker T, Brockhoff G, Hofstädter F, Fishel R: Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection. Proc Natl Acad Sci 95:11301–11306, 1998
Azumaya M, Kobayashi M, Ajioka Y, Honma T, Suzuki Y, Takeuchi M, Narisawa R, Asakura H: Size-dependent expression of cyclooxygenase-2 in sporadic colorectal adenomas relative to adenomas in patients with familial adenomatous polyposis. Pathology Int 52:272–276, 2002
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Brazowski, E., Misonzhnick-Bedny, F. & Rozen, P. Cyclooxygenase-2 Expression in the Hereditary Mixed Polyposis Syndrome. Dig Dis Sci 49, 1906–1911 (2004). https://doi.org/10.1007/s10620-004-9591-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-004-9591-2